As CRISPR-Cas adoption soars, summit calls for genome editing oversight.
Nature biotechnology, 36(6): 485 PMID 29874214 DOI 10.1038/nbt0618-485
Abstract
This article has no abstract in PubMed.
Your browser does not allow saving data (e.g. private mode): bookmarks will be lost when the tab closes.